$103.67 -0.63 (%) Johnson & Johnson - NYSE

Oct. 2, 2014 | 12:27 PM

Partner Headlines

  1. Johnson & Johnson Falls On Bernstein Downgrade

    Benzinga | Oct. 1, 2014 | 15:09PM EST
  2. Stocks Sell Off On Europe Worries; Growth Names Slammed

    IBD | Oct. 1, 2014 | 15:04PM EST
  3. Why Mega-Cap Stocks Are Beating Broader Market

    YCharts | Oct. 1, 2014 | 12:02PM EST
  4. Benzinga's Top Downgrades

    Benzinga | Oct. 1, 2014 | 08:53AM EST
  5. Bernstein Downgrades Johnson & Johnson To Market Perform, Shares Drop

    Benzinga | Oct. 1, 2014 | 08:13AM EST
  6. J&J Moves Into Gilead's Turf

    IBD | Sep. 30, 2014 | 18:43PM EST
  7. Ireland Exporters Look To Thursday's ECB Policy Vote

    IBD | Sep. 30, 2014 | 18:24PM EST
  8. Stocks Move To Session Lows; Regeneron Rises On Drug Data

    IBD | Sep. 30, 2014 | 15:04PM EST
  9. Achillion Pharmaceuticals, Inc. Less Attractive Amid Johnson & Johnson/Alios BioPharma Deal

    Benzinga | Sep. 30, 2014 | 12:19PM EST
  10. J&J Buying Alios, Going Up Against Gilead

    IBD | Sep. 30, 2014 | 12:02PM EST
  11. #PreMarket Primer: Thursday, September 25: US Airstrikes Do Little To Stem ISIS Advances

    Benzinga | Sep. 25, 2014 | 07:27AM EST
  12. International Securities For A Diversified Income Portfolio

    GuruFocus | Sep. 23, 2014 | 13:36PM EST
  13. "A Unique Period of Time," Revisited

    GuruFocus | Sep. 22, 2014 | 10:48AM EST
  14. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD | Sep. 19, 2014 | 12:17PM EST
  15. Stocks Hitting 52-Week Highs

    Benzinga | Sep. 19, 2014 | 10:02AM EST
  16. New Active ETF for All Risk Environments

    Benzinga | Sep. 17, 2014 | 10:05AM EST
  17. 3 Companies Investing In Stem Cell Research

    Benzinga | Sep. 14, 2014 | 16:34PM EST
  18. Addressing Disengagement And Depression Lifts Workers

    IBD | Sep. 12, 2014 | 14:41PM EST
  19. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD | Sep. 11, 2014 | 17:41PM EST
  20. Steadier, Better: 35 Years Of Low-Volatility Stocks

    YCharts | Sep. 8, 2014 | 20:54PM EST
  21. Johnson & Johnson Metal Hip Might Lead To Poisoning, Facing 6,000+ Suits

    Benzinga | Sep. 4, 2014 | 17:16PM EST
  22. US Stock Futures Gain; ADP, Jobless Claims Data In Focus

    Benzinga | Sep. 4, 2014 | 07:35AM EST
  23. Sharper Focus Pays Dividends At Johnson & Johnson

    IBD | Sep. 3, 2014 | 16:29PM EST
  24. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD | Sep. 3, 2014 | 16:22PM EST
  25. Infinity Pharma Joins AbbVie On Blood Cancer Drug

    IBD | Sep. 3, 2014 | 13:20PM EST
  26. Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

    Benzinga | Sep. 2, 2014 | 09:10AM EST
  27. U.S., U.K. ISIS Response Differ Widely

    FoxBusiness | Aug. 29, 2014 | 11:34AM EST
  28. Bank Of America Remains Optimistic On Johnson & Johnson

    Benzinga | Aug. 29, 2014 | 09:13AM EST
  29. Morgan Stanley Sees More Focused Device Strategy Continue For Johnson & Johnson

    Benzinga | Aug. 29, 2014 | 08:47AM EST
  30. Focus On A Big-Picture Purpose To Get Top Results

    IBD | Aug. 28, 2014 | 13:18PM EST
  31. Think Like An Owner

    GuruFocus | Aug. 27, 2014 | 17:07PM EST
  32. Late-Cycle Nirvana: Moaty Dividends on the Cheap

    YCharts | Aug. 25, 2014 | 23:48PM EST
  33. The 4 Companies Teaming Up For A New Tool To Fight Cancer

    Benzinga | Aug. 25, 2014 | 16:03PM EST
  34. Here's Why Johnson & Johnson Is a Good Investment at 52-Week Highs

    GuruFocus | Aug. 25, 2014 | 12:57PM EST
  35. Omnicom Offers Steady Profit Growth, Rising Dividend

    IBD | Aug. 22, 2014 | 17:25PM EST
  36. #PreMarket Primer: Friday, August 22: Draghi, Yellen Set To Speak At Jackson Hole

    Benzinga | Aug. 22, 2014 | 07:07AM EST
  37. Illumina lines up key partners

    IBD | Aug. 21, 2014 | 18:41PM EST
  38. Apple Stock Held By Institutional Investors Rises

    IBD | Aug. 21, 2014 | 17:02PM EST
  39. A Few Reasons Why Investors Should Consider Dendreon for Their Portfolio

    GuruFocus | Aug. 15, 2014 | 12:18PM EST
  40. Robert Wood Johnson's New Industry Made Surgery Safer

    IBD | Aug. 14, 2014 | 13:57PM EST
  41. Earnings Season Is The Right Prescription For Health Care ETFs

    Benzinga | Aug. 12, 2014 | 16:53PM EST
  42. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD | Aug. 12, 2014 | 10:48AM EST
  43. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD | Aug. 8, 2014 | 11:55AM EST
  44. 3 Companies That Should Benefit From The New Initiative In Africa

    Benzinga | Aug. 7, 2014 | 09:40AM EST
  45. #PreMarket Primer: Thursday, August 7: Russia Set To Release A List Of Banned Goods

    Benzinga | Aug. 7, 2014 | 07:03AM EST
  46. 5 Dividend Stocks Delivering The Secret To Successful Investing

    GuruFocus | Aug. 6, 2014 | 11:55AM EST
  47. 5 Dividend Stocks Delivering The Secret To Successful Investing

    GuruFocus | Aug. 5, 2014 | 11:56AM EST
  48. Amgen Cancer Drug Kyprolis Succeeds In Trial

    IBD | Aug. 4, 2014 | 10:56AM EST
  49. Why Procter & Gamble Surged Higher On Friday?

    GuruFocus | Aug. 3, 2014 | 09:51AM EST
  50. Outlook for August 2014

    GuruFocus | Aug. 1, 2014 | 18:48PM EST
Trading Center